JP2015511635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511635A5 JP2015511635A5 JP2015503112A JP2015503112A JP2015511635A5 JP 2015511635 A5 JP2015511635 A5 JP 2015511635A5 JP 2015503112 A JP2015503112 A JP 2015503112A JP 2015503112 A JP2015503112 A JP 2015503112A JP 2015511635 A5 JP2015511635 A5 JP 2015511635A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- olmesartan medoxomil
- weight
- composition according
- compartment containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims description 18
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims description 18
- 229960001199 olmesartan medoxomil Drugs 0.000 claims description 18
- 239000007884 disintegrant Substances 0.000 claims description 16
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 14
- 229960000672 rosuvastatin Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 5
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 229940032147 starch Drugs 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 239000008109 sodium starch glycolate Substances 0.000 claims description 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229940071117 starch glycolate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000007906 compression Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120032903 | 2012-03-30 | ||
| KR10-2012-0032903 | 2012-03-30 | ||
| PCT/KR2013/002378 WO2013147462A1 (en) | 2012-03-30 | 2013-03-22 | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511635A JP2015511635A (ja) | 2015-04-20 |
| JP2015511635A5 true JP2015511635A5 (enExample) | 2016-05-12 |
| JP6122098B2 JP6122098B2 (ja) | 2017-04-26 |
Family
ID=49260650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503112A Active JP6122098B2 (ja) | 2012-03-30 | 2013-03-22 | オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150050333A1 (enExample) |
| EP (1) | EP2830618B1 (enExample) |
| JP (1) | JP6122098B2 (enExample) |
| KR (2) | KR101451081B1 (enExample) |
| CN (1) | CN104220068B (enExample) |
| AU (1) | AU2013240846B2 (enExample) |
| CA (1) | CA2866377C (enExample) |
| CL (1) | CL2014002581A1 (enExample) |
| CY (1) | CY1117909T1 (enExample) |
| DK (1) | DK2830618T3 (enExample) |
| ES (1) | ES2587912T3 (enExample) |
| HU (1) | HUE030674T2 (enExample) |
| IN (1) | IN2014MN01919A (enExample) |
| LT (1) | LT2830618T (enExample) |
| MX (1) | MX362400B (enExample) |
| MY (1) | MY166288A (enExample) |
| PH (2) | PH12014501813B1 (enExample) |
| PT (1) | PT2830618T (enExample) |
| RU (1) | RU2616516C2 (enExample) |
| SG (2) | SG10201502582PA (enExample) |
| WO (1) | WO2013147462A1 (enExample) |
| ZA (1) | ZA201407544B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0752842Y2 (ja) | 1989-10-04 | 1995-12-06 | タカヤマ金属工業株式会社 | 樋支持具 |
| EP3219318A4 (en) * | 2014-11-11 | 2018-07-11 | Shionogi & Co., Ltd. | Multi-layered tablet containing drug unstable with respect to light |
| WO2016112389A1 (en) * | 2015-01-09 | 2016-07-14 | Autotelic Llc | Methods for olmesartan dosing by auc |
| CN105395551A (zh) * | 2015-11-19 | 2016-03-16 | 哈尔滨圣吉药业股份有限公司 | 一种奥美沙坦酯/瑞舒伐他汀复方制剂及其制备方法 |
| CN106727580A (zh) * | 2015-11-19 | 2017-05-31 | 哈尔滨圣吉药业股份有限公司 | 一种阿利沙坦酯/瑞舒伐他汀复方制剂及其制备方法 |
| CN105232556A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种坎地沙坦酯/瑞舒伐他汀复方制剂及其制备方法 |
| CN105232555A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法 |
| CN106727579A (zh) * | 2015-11-19 | 2017-05-31 | 哈尔滨圣吉药业股份有限公司 | 一种厄贝沙坦/瑞舒伐他汀复方制剂及其制备方法 |
| TW201726744A (zh) | 2016-01-11 | 2017-08-01 | 奧托德里克有限公司 | 用於檢測奧美沙坦(olmesartan)及改善治療高血壓之遵從性的組成物、裝置及方法 |
| WO2018009842A1 (en) * | 2016-07-08 | 2018-01-11 | Autotelic Llc | Methods for rosuvastatin dosing by auc |
| CN110913843B (zh) * | 2017-07-17 | 2022-09-13 | 伊莱利利公司 | 药物组合物 |
| KR101992400B1 (ko) * | 2018-04-30 | 2019-06-24 | 보령제약 주식회사 | 약학적 제제 |
| MX2021010183A (es) * | 2019-02-26 | 2021-09-21 | Daewoong Pharmaceutical Co Ltd | Composicion farmaceutica con forma de dosificacion unica para tratar o prevenir la hipertension y la hiperlipidemia. |
| KR20220026641A (ko) * | 2020-08-25 | 2022-03-07 | 주식회사 대웅제약 | 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 |
| CN113398086A (zh) * | 2021-05-18 | 2021-09-17 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
| CN113476423A (zh) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1054019A1 (en) * | 1999-05-18 | 2000-11-22 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose |
| JP2002145770A (ja) * | 2000-08-30 | 2002-05-22 | Sankyo Co Ltd | 心不全の予防又は治療のための医薬組成物 |
| BRPI0713371A2 (pt) * | 2006-06-27 | 2012-03-13 | Daiichi Sankyo Company, Limited | método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil |
| US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
| MX2009004681A (es) * | 2006-10-30 | 2009-08-19 | Hanall Pharmaceutical Co Ltd | Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa. |
| WO2008068217A2 (en) * | 2006-12-04 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
| CN101594865A (zh) * | 2006-12-07 | 2009-12-02 | 第一三共株式会社 | 含有低取代的羟基丙基纤维素的药物组合物 |
| TWI488658B (zh) * | 2006-12-26 | 2015-06-21 | Daiichi Sankyo Co Ltd | 溶出性之改善方法 |
| TW200927197A (en) * | 2007-10-29 | 2009-07-01 | Daiichi Sankyo Co Ltd | Film coated preparation |
| WO2009073683A2 (en) * | 2007-12-04 | 2009-06-11 | Schering Corporation | Methods of treating copd |
| WO2009154810A2 (en) * | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
| WO2009113420A1 (ja) * | 2008-03-13 | 2009-09-17 | 第一三共株式会社 | オルメサルタンメドキソミルを含む製剤の溶出性の改善 |
| KR20090114190A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물 |
| US10574932B2 (en) * | 2008-07-28 | 2020-02-25 | Fox Digital Enterprises, Inc. | System and method of generating subtitling for media |
| CN102548544B (zh) * | 2009-10-09 | 2015-01-21 | 永进药品工业株式会社 | 同时具有速效特性和长效特性的药物组合物 |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| EP2438911A1 (en) * | 2010-10-08 | 2012-04-11 | LEK Pharmaceuticals d.d. | Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil |
| US8399011B1 (en) * | 2012-08-10 | 2013-03-19 | Magnifica Inc. | Oral particle compositions containing a core and an acid-soluble coat |
-
2013
- 2013-03-22 SG SG10201502582PA patent/SG10201502582PA/en unknown
- 2013-03-22 LT LTEP13769567.2T patent/LT2830618T/lt unknown
- 2013-03-22 HU HUE13769567A patent/HUE030674T2/en unknown
- 2013-03-22 IN IN1919MUN2014 patent/IN2014MN01919A/en unknown
- 2013-03-22 MX MX2014011510A patent/MX362400B/es active IP Right Grant
- 2013-03-22 KR KR1020130030734A patent/KR101451081B1/ko active Active
- 2013-03-22 SG SG11201405198YA patent/SG11201405198YA/en unknown
- 2013-03-22 PT PT137695672T patent/PT2830618T/pt unknown
- 2013-03-22 CA CA2866377A patent/CA2866377C/en active Active
- 2013-03-22 EP EP13769567.2A patent/EP2830618B1/en active Active
- 2013-03-22 DK DK13769567.2T patent/DK2830618T3/en active
- 2013-03-22 ES ES13769567.2T patent/ES2587912T3/es active Active
- 2013-03-22 AU AU2013240846A patent/AU2013240846B2/en active Active
- 2013-03-22 WO PCT/KR2013/002378 patent/WO2013147462A1/en not_active Ceased
- 2013-03-22 US US14/388,115 patent/US20150050333A1/en not_active Abandoned
- 2013-03-22 CN CN201380018083.0A patent/CN104220068B/zh active Active
- 2013-03-22 MY MYPI2014002534A patent/MY166288A/en unknown
- 2013-03-22 RU RU2014143536A patent/RU2616516C2/ru active
- 2013-03-22 JP JP2015503112A patent/JP6122098B2/ja active Active
-
2014
- 2014-06-19 KR KR1020140074778A patent/KR101931195B1/ko active Active
- 2014-08-11 PH PH12014501813A patent/PH12014501813B1/en unknown
- 2014-09-26 CL CL2014002581A patent/CL2014002581A1/es unknown
- 2014-10-17 ZA ZA2014/07544A patent/ZA201407544B/en unknown
-
2016
- 2016-03-03 PH PH12016500420A patent/PH12016500420A1/en unknown
- 2016-08-11 CY CY20161100799T patent/CY1117909T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511635A5 (enExample) | ||
| RU2014143536A (ru) | Фармацевтическая композиция, содержащая омелсартана медоксомил и розувастатин или его соль | |
| TWI700100B (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物及其製備方法 | |
| JP2010522244A5 (enExample) | ||
| PH12015502134B1 (en) | Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration | |
| JP2012144577A5 (enExample) | ||
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| AR069031A1 (es) | Composicion | |
| JPWO2009104739A1 (ja) | 経口投与用固形製剤 | |
| NO341027B1 (no) | Tablett med høyt medikamentinnhold og fremgangsmåte for fremstilling derav | |
| JP2012031131A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| JP2016530238A5 (enExample) | ||
| JP2016108327A5 (enExample) | ||
| JP2014218523A5 (enExample) | ||
| EP2934488A1 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
| JP2019504848A5 (enExample) | ||
| JP2017523149A5 (enExample) | ||
| JP2017520619A5 (enExample) | ||
| JP2015120758A5 (enExample) | ||
| JP2015129124A5 (enExample) | ||
| JP2014118380A (ja) | ベンズイミダゾール−７−カルボン酸誘導体含有錠剤組成物 | |
| RU2018100755A (ru) | Комбинированный препарат мозаприда и рабепразола | |
| CN102697749A (zh) | 盐酸贝那普利片的制备方法 |